Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, double blind, multicentre, placebo controlled phase III study of the safety and tolerability following administration of live attenuated JE [Japanese encephalitis] vaccine (ChimeriVax-JE)

Next Previous
X
Search
Trial Profile

Randomised, double blind, multicentre, placebo controlled phase III study of the safety and tolerability following administration of live attenuated JE [Japanese encephalitis] vaccine (ChimeriVax-JE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Japanese encephalitis vaccine (Primary)
  • Indications Japanese encephalitis
  • Focus Adverse reactions; Registrational
  • Sponsors Sanofi Pasteur Holding

    • Most Recent Events

    • 08 Jul 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry, ACTRN12605000575639).
    • 26 Jan 2009 Actual end date (Nov 2006) added as reported by ClinicalTrials.gov.
    • 26 Jan 2009 Actual initiation date (Oct 2005) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top